Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Areva P0013
- Development stage
- Preclinical
- Lead developer
- Areva Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Areva P0013 is an injectable small molecule pharmaceutical product currently under development by Areva Pharmaceuticals. The drug is being developed through the 505(b)(2) regulatory pathway, which typically involves a modification—such as a new dosage form, strength, or formulation—of a previously approved drug. Areva P0013 is available in 500mg and 1g dosage strengths. While the specific therapeutic indication and biological target have not been publicly disclosed, Areva Pharmaceuticals focuses primarily on injectable oncology and supportive care pharmaceuticals. The company expects to reach a milestone for an NDA/BLA filing in the fourth quarter of 2026.
Beyond the preview
Go deeper on Areva P0013.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Areva P0013.